Re­call re­port: Fre­se­nius Kabi yanks in­flam­ma­to­ry med Ke­toro­lac af­ter find­ing par­tic­u­lates in vials

The FDA on Fri­day an­nounced that Fre­se­nius Kabi USA, based in Illi­nois, vol­un­tar­i­ly re­called a sin­gle lot of Ke­toro­lac Tromethamine In­jec­tion USP 30 mg/mL. Par­tic­u­late mat­ter was found in re­serve sam­ple vials of the drug, which is used as a short-term med­ica­tion to man­age se­vere acute pain which re­quires anal­ge­sia at the opi­oid lev­el.

Fre­se­nius Kabi USA has re­ceived no re­ports of neg­a­tive side ef­fects from the lot, the FDA said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER